Saakshi Medtech

Why is Saakshi Medtech & Panels Ltd falling/rising?

As of 11-Jun, Saakshi Medtech & Panels Ltd's stock price has risen to 256.00, reflecting an increase of 4.49%. This rise is driven by strong performance compared to the benchmark Sensex, significant year-to-date gains, and trading above key moving averages, despite a decline in investor participation.

As of 11-Jun, Saakshi Medtech & Panels Ltd is experiencing a rise in its stock price, currently at 256.00, which reflects an increase of 11.0 or 4.49%. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed the benchmark Sensex, showing a performance today that is 4.68% higher than its sector. Additionally, over the past week, the stock has increased by 4.07%, while the Sensex has declined by 1.09%. This trend of outperformance is also evident in the longer-term metrics, with the stock showing a year-to-date increase of 36.17% compared to a decrease of 11.36% in the Sensex, and a one-year increase of 54.22% against a decline of 7.87% in the benchmark.<BR><BR>Moreover, Saakshi Medtech is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong bullish trend. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 12.09% against the 5-day average. Despite this drop in participation, the stock remains liquid enough for trading.<BR><BR>In summary, the combination of strong performance relative to the benchmark, positive price movements above key moving averages, and substantial year-to-date gains contribute to the rising stock price of Saakshi Medtech & Panels Ltd.

Which are the latest news on Saakshi Medtech?

What does Saakshi Medtech do?

Saakshi Medtech & Panels Ltd is a Micro Cap company in the Other Electrical Equipment industry, originally incorporated in 2009. It has no recent sales or profit data, with a market cap of INR 450 Cr and key metrics including a P/E of 35.00 and a debt-equity ratio of 0.21.

Overview:<BR>Saakshi Medtech & Panels Ltd operates in the Other Electrical Equipment industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited Company under the name "Saakshi Machine and Tools Private Limited" on March 25, 2009. It later took over the business of a proprietorship concern on January 27, 2012. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 450 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00<BR>Industry P/E: 93<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.21<BR>Return on Equity: 11.14%<BR>Price-to-Book: 4.05<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

How big is Saakshi Medtech?

As of 10th June, Saakshi Medtech & Panels Ltd has a market capitalization of 450.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest four quarters, but as of March 2025, Shareholder's Funds are 98.04 Cr and Total Assets are 131.10 Cr.

As of 10th June, <BR><BR>Market Cap: Saakshi Medtech & Panels Ltd has a market capitalization of 450.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 98.04 Cr and Total Assets valued at 131.10 Cr.

Who are the peers of the Saakshi Medtech?

Saakshi Medtech's peers include Australian Prem, Artemis Electri., RMC Switchgears, GEE, Magnus Steel, and Delton Cables. Saakshi Medtech has a 1-year return of 45.78%, significantly outperforming its peers, with varying management risks and growth ratings among them.

Peers: The peers of Saakshi Medtech are Australian Prem, Artemis Electri., RMC Switchgears, GEE, Magnus Steel, and Delton Cables.<BR><BR>Quality Snapshot: Excellent management risk is observed at Australian Prem and Magnus Steel, while Average management risk is found at Saakshi Medtech and Delton Cables. Below Average management risk is seen at Saakshi Medtech, Artemis Electri., and GEE. Excellent growth is noted at Australian Prem and Magnus Steel, while Good growth is observed at Saakshi Medtech and RMC Switchgears. Below Average growth is found at Artemis Electri. and GEE, and the rest have Average or lower ratings. Excellent capital structure is seen at Australian Prem, while Good capital structure is noted at Saakshi Medtech and RMC Switchgears, with Average capital structure at Magnus Steel and Delton Cables, and the rest having Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Saakshi Medtech at 45.78%, while the peer with the lowest is Australian Prem at -50.66%. Saakshi Medtech's return is significantly higher compared to its peers. Additionally, GEE, Magnus Steel, and Delton Cables have a six-month return of 0.00%.

How has been the historical performance of Saakshi Medtech?

Saakshi Medtech has experienced a decline in key financial metrics, with net sales and operating profit decreasing from Mar'23 to Mar'25, while total assets and liabilities increased. Cash flow from operations also fell significantly, indicating reduced profitability despite asset growth.

Answer:<BR>The historical performance of Saakshi Medtech shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Saakshi Medtech's net sales have decreased from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25. The raw material costs also decreased from 73.93 Cr in Mar'23 to 58.81 Cr in Mar'25, indicating a reduction in production costs. Operating profit (PBDIT) saw a decline from 20.70 Cr in Mar'23 to 10.88 Cr in Mar'25, with the operating profit margin decreasing from 16.84% to 11.15%. Profit before tax fell from 16.59 Cr in Mar'23 to 6.59 Cr in Mar'25, leading to a profit after tax of 4.71 Cr in Mar'25, down from 12.38 Cr in Mar'23. The company's total assets increased from 93.24 Cr in Mar'23 to 131.10 Cr in Mar'25, while total liabilities also rose from 93.24 Cr to 131.10 Cr in the same period. Cash flow from operating activities decreased from 10.00 Cr in Mar'23 to 3.00 Cr in Mar'25, contributing to a net cash outflow of 12.00 Cr in Mar'25. Overall, Saakshi Medtech's financial performance has shown a decline in profitability and cash flow, despite an increase in total assets and liabilities.

Is Saakshi Medtech overvalued or undervalued?

As of November 6, 2025, Saakshi Medtech is considered very expensive and overvalued with a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a year-to-date return of -22.64%, significantly underperforming compared to its peers and the Sensex.

As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors.<BR><BR>The company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment.

Who are the top shareholders of the Saakshi Medtech?

The top shareholders of Saakshi Medtech include promoter Chitra Vijay Latkar with 66.27%, individual investors with 22.37%, and public shareholder Jatinder Agarwal at 4.84%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Saakshi Medtech include the promoters, with Chitra Vijay Latkar holding the largest share at 66.27%. Additionally, individual investors collectively own 22.37% of the company. The highest public shareholder is Jatinder Agarwal, who holds 4.84%. There are also two foreign institutional investors (FIIs) that hold a combined 0.1%. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

What is the technical trend for Saakshi Medtech?

As of June 3, 2025, Saakshi Medtech's trend has shifted to sideways with mixed signals; while the weekly MACD and KST are mildly bullish, daily moving averages and monthly Bollinger Bands indicate a mildly bearish outlook, reflecting overall market indecision.

As of 3 June 2025, the technical trend for Saakshi Medtech has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a bullish signal on the weekly chart but are mildly bearish on the monthly chart. The KST and OBV are both mildly bullish on the weekly timeframe, supporting the sideways trend. Overall, the strength of the trend is weak, reflecting indecision in the market.

When is the next results date for Saakshi Medtech?

No Upcoming Board Meetings

Has Saakshi Medtech declared dividend?

No Dividend History Available